BioRender is now remote-first, with plans to bring everyone together at our Toronto office a few times each year.
We are committed to providing work environments which promote the health, safety and well-being of all employees in accordance with public health regulation and guidance.
BioRender is an equal opportunity employer and, as such, does not discriminate on the basis of race, colour, religion, sex, national origins, age, sexual orientation, disability or any other characteristic protected by applicable laws. Selection decisions are solely based on job-related factors.
Read more about our BioRender interview process & FAQs here!
Check out what it's like to work at BioRender in Canada and the US!
#LI-HC1
Full-Time
Confirmed live in the last 24 hours
Online platform for creating scientific illustrations
No salary listed
Senior
Remote in USA + 1 more
More locations: Remote in Canada
Remote-first with plans to bring everyone together at the Toronto office a few times each year.
Upload your resume to see how it matches 7 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
BioRender provides an online platform for creating and sharing scientific illustrations tailored for the life sciences sector. Users can access thousands of pre-drawn icons and templates across more than 30 life sciences fields, allowing scientists, researchers, and educators to produce professional and visually appealing figures efficiently. The platform is designed to simplify the illustration process, making it easier for clients such as academic researchers, pharmaceutical companies, and educational institutions to create figures for research papers, presentations, and educational materials. BioRender operates on a subscription-based model, offering various plans that cater to different user needs, including enterprise solutions for larger organizations. The company's goal is to streamline the creation of scientific figures, saving users time and effort while enhancing the quality of scientific communication.
Company Size
201-500
Company Stage
Series A
Total Funding
$17.2M
Headquarters
Toronto, Canada
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Flexible Work Hours
Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they found, helps to kick off a series of events involving the transport of specific nuclear proteins that lead to uncontrolled tumor growth, according to a study published Nov. 11, 2024, in Nature Cancer
Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis
Cancer cells surround themselves with a cloud of adenosine, thereby inhibiting the immune system (left). Ceritinib stops the formation of adenosine. ATP accumulates and activates immune cells (right). Figure: Laura Schäkel/University of Bonn – created with BioRender.com. German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system
Today BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.